Teva Pharmaceutical, based in Israel, landed the first FDA approval for a digital inhaler with built-in sensors. The ProAir Digihaler (albuterol sulfate 117 mcg) Inhalation Powder is indicated for people suffering from asthma & COPD as a way of preventing and treating bronchospasm, a tightening of the muscles that line the airways.
The ProAir Digihaler monitors how it’s used and uploads the data to an accompanying smartphone app via Bluetooth wireless connectivity. Specifically, the device detects every time it has been used to administer treatment, as well as the inspiratory airflow during each inhalation.
“There are 25 million Americans living with asthma, many of whom use inhalers as part of their treatment regimen. Despite advancements in care over the years, we know that many are using their rescue medications incorrectly or too often,” in a published statement said Tonya Winders, President & CEO of the Allergy & Asthma Network.
The ProAir Digihaler device from Teva Pharmaceutical Industries is a digital inhaler that uses sensors to connect to a companion smartphone app for people who have asthma and chronic obstructive pulmonary disease, according to the company.
Using built-in sensors, the ProAir Digihaler can measure inspiratory flow and detect when the inhaler is used. Then, the data can be sent to the smartphone app where users can review historical data and share it with their healthcare professionals. Read more:
Also Read: TALIKA Pigment Control – Anti-Dark Spot Cosmetic Device
